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ORIGINAL ARTICLE
VA Healthcare Costs of a Collaborative Intervention for
Chronic Pain in Primary Care
Kathryn C. Dickinson, MPH,* Rajiv Sharma, PhD,*† Jonathan P. Duckart, MPS,*
Kathryn Corson, PhD,*‡ Martha S. Gerrity, MD,*§¶ and Steven K. Dobscha, MD*‡
Background: Chronic pain is costly to individuals and the health-
care system, and is often undertreated. Collaborative care models
show promise for improving treatment of patients with chronic pain.
The objectives of this article are to report the incremental benefit and
incremental health services costs of a collaborative intervention for
chronic pain from a veterans affairs (VA) healthcare perspective.
Methods: Data on VA treatment costs incurred by participants were
obtained from the VA’s Decision Support System for all utilization
except certain intervention activities which were tracked in a sepa-
rate database. Outcome data were from a cluster-randomized trial of
a collaborative intervention for chronic pain among 401 primary
care patients at a VA medical center. Intervention group participants
received assessments and care management; stepped-care compo-
nents were offered to patients requiring more specialized care. The
main outcome measure was pain disability-free days (PDFDs),
calculated from Roland-Morris Disability Questionnaire scores.
Results: Participants in the intervention group experienced an av-
erage of 16 additional PDFDs over the 12-month follow-up window
as compared with usual care participants; this came at an adjusted
incremental cost of $364 per PDFD for a typical participant. Impor-
tant predictors of costs were baseline medical comorbidities, depres-
sion severity, and prior year’s treatment costs.
Conclusions: This collaborative intervention resulted in more pain
disability-free days and was more expensive than usual care. Further
research is necessary to identify if the intervention is more cost-
effective for some patient subgroups and to learn whether pain
improvements and higher costs persist after the intervention has
ended.
Key Words: chronic pain, collaborative care, pain improvement,
cost, primary care
(Med Care 2010;48: 38–44)
Chronic, noncancer pain is associated with considerablephysical and psychosocial impairment, and increased
healthcare utilization and costs.1–4 Chronic pain results not
only in direct costs for treatment but also in increased
disability compensation, decreased productivity, and lost tax
revenue.3 It is estimated that common pain conditions cost the
United States $61.2 billion per year in lost productive time
alone.5 There are many approaches to treating chronic pain,
including medications, surgery, physical therapy, anesthesi-
ology interventions, multidisciplinary pain centers, behav-
ioral interventions, and alternative therapies such as chiro-
practic manipulation and acupuncture; many are expensive
and rarely offer a complete cure.3 Chronic pain patients are
frequently managed with medications such as opioids, and
medication costs can easily exceed $4000 per year.3 Provid-
ers and patients often search for a satisfactory combination of
treatments to ease suffering and increase functional status,
while minimizing costs to the individual and the healthcare
system.
Collaborative care interventions based in primary care
have emerged as one successful approach to supporting guide-
line-concordant care and improving outcomes for chronic con-
ditions.6–8 These interventions are based on the chronic care
model developed by Wagner et al9; they seek to optimize
patient-clinician interactions while providing system support,
typically in the form of patient activation, clinician feedback,
and care management. The “Study of the Effectiveness of A
Collaborative Approach to Pain” (SEACAP) sought to assess
whether a novel collaborative care intervention would result
in improvements in chronic pain and depression outcomes
compared with treatment as usual (TAU) among patients
treated in a veterans affairs (VA) primary care setting.10,11
SEACAP showed modest effects, with intervention patients
showing greater improvements in self-reported pain-related
disability, pain interference, pain intensity, global impression
of change, and depression over 12 months compared with
TAU patients. The differences in scores between baseline and
12 months for the intervention group and the TAU group,
respectively, were 1.4 versus 0.2 for the Roland-Morris
Disability Questionnaire (RMDQ)12,13 (pain-related disabil-
ity, SEACAP’s primary outcome), 4.7 versus 0.6 for the
Chronic Pain Grade Pain Intensity subscale,14 and 3.7
versus1.2 for the Patient Health Questionnaire-915 (depres-
sion). The objectives of this manuscript are to report the
incremental benefit (described in pain disability-free days)
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and incremental health services costs of the SEACAP inter-
vention from a VA healthcare perspective.
METHODS
Design
SEACAP was a cluster-randomized trial of a collabo-
rative intervention entitled “Assistance with Pain Treatment”
(APT). APT was designed to educate and activate patients
and clinicians, and to facilitate care. APT and SEACAP design
and results have been described in detail elsewhere.10,11 The VA
Medical Center (VAMC) institutional review board approved
the study and all patients and participating primary care clini-
cians gave written informed consent.
SEACAP was conducted in 3 urban and 2 rural primary
care clinics of 1 VAMC. All staff primary care clinicians
were eligible to participate (N  54). Of the 46 who agreed
to participate, 2 left their VA primary care practices before
patient enrollment began and 2 had no patients enroll. The
remaining clinicians were randomly assigned to intervention
(n  20) or TAU (n  22) prior to patient recruitment using
stratified random assignment. Randomization was stratified
by professional training (nurse practitioner or physician as-
sistant vs. physician), the proportion of their patients cur-
rently receiving opioid prescriptions, and distance from the
main VAMC site (15 vs. 15 miles). We detected no
differences between participating and nonparticipating clini-
cians in terms of professional training, distance from the main
hospital, proportion of patients receiving prescriptions for
opioids, or panel size. Patients enrolled in the trial were
assigned to the same group as their primary care clinicians,
yielding 187 in the intervention group and 214 in TAU.
Inclusion criteria were medical record documentation
of a musculoskeletal pain diagnosis, pain of at least 12 weeks
duration, Chronic Pain Grade14 intensity and interference
item scores each 4 (indicating moderate or greater sever-
ity), and regular access to a telephone. Exclusion criteria
included previously documented diagnoses of fibromyalgia,
chronic fatigue syndrome, or somatization disorder. We also
excluded patients with bipolar disorder, psychotic disorder,
dementia, terminal illness, suicidal ideation requiring urgent
attention, and patients whose medical records contained spe-
cial flags indicating a history of disruptive behavior.
Treatment
APT is based on Wagner’s chronic care model,9 previ-
ous collaborative interventions7,16–20 and multidisciplinary
pain approaches,21–24 chronic pain treatment guideline crite-
ria having at least fair to moderate evidence supporting their
impact on pain outcomes,25–27 and brief activating interven-
tions for back pain.28 The 2 key members of the APT team
were a full-time clinical psychologist care manager and a
VAMC internist who spent up to 1 day per week on APT
team activities. A physical therapist also participated in some
group educational meetings. Clinicians in the intervention
group received an initial educational program followed by
ongoing contacts with the APT team for feedback and rec-
ommendations. All intervention group patients received as-
sessments and care management, while stepped-care compo-
nents such as APT internist or mental health consultation
were offered to those patients requiring more intensive or
specialized care approaches. During initial assessments, the
care manager sought to identify fear-avoidance beliefs, such
as fear of movement or of pain exacerbations, explored for
treatment barriers, screened for comorbid psychiatric disor-
ders (including depression and substance misuse), and devel-
oped individualized functional goals. The care manager and
intervention internist then developed treatment recommenda-
tions that were communicated to the patient’s primary care
clinician. In some cases, the internist also interacted directly
with patients to discuss symptoms or provide additional
support. Patients were contacted by the care manager every 2
months after the initial assessment for follow-up, goal mod-
ification, encouragement, and administration of pain, depres-
sion, and alcohol measures. Additionally, intervention partic-
ipants were encouraged to attend a 4-session workshop co-led
by the care manager and internist or physical therapist;
sessions included education, skill practice, and support for
goal setting and attainment. The TAU group received routine
pain care from their primary care clinicians. Both TAU and
intervention clinicians had access to the specialty pain clinic,
ancillary services including physical, occupational, and rec-
reational therapies, and co-located mental health services.
Outcome Measures
For SEACAP main analyses, the primary outcome
measure was the RMDQ.12,13 The RMDQ has content and
construct validity, internal consistency, and responsiveness to
pain among patients with chronic pain.13,29 For the cost
effectiveness analysis, the primary outcome was the number
of pain disability-free days (PDFDs) that patients experienced
during the 12-month study period. We had considered also
analyzing EQ-5D quality of life scores but there were no
differences between TAU and intervention patients, perhaps
because the EQ-5D may not be sensitive enough to detect
small to moderate changes.30,31 The number of PDFDs was
computed from 3, 6, and 12 month RMDQ scores following
methods similar to those employed by Lave et al32 to com-
pute depression-free days.33,34 RMDQ scores at the begin-
ning and end of each time interval were used to estimate pain
disability for each day in that interval; we regarded patients
with scores of 5 or lower as fully pain disability free and
those with scores of 19 or higher as fully pain disabled.35,36
For patients with RMDQ scores from 6 to 18, the proportion
of days spent in pain disability was assumed to increase
linearly with the score. The total number of PDFDs over the
study period was obtained by summing PDFDs across time
intervals.
Costs
Data on VA treatment costs incurred by intervention
and TAU group patients were obtained directly from the
VA’s Decision Support System (DSS) for all utilization
except certain APT team activities that were not recorded in
this system. DSS contains comprehensive information on
fixed, variable, and indirect costs incurred by the VA on all
inpatient, outpatient, surgical, and pharmaceutical utilization,
but does not include all costs related to outside healthcare
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providers or financing of capital expenses.37 DSS employs a
microcosting approach whereby treatment costs are computed
by cumulating the costs of individual components of the
treatment.38,39 The DSS system has been used for other VA
cost analyses.34,40
The intervention team used a Microsoft Access data-
base to keep track of activities not recorded in DSS; this
included time spent on telephone and in-person contacts with
participants which they estimated on a daily or weekly basis
depending on the frequency of the activity. DSS costs for
comparable activities were used to approximate costs of APT
team patient care activities that were not recorded in the DSS
system. Contact duration (time), contact type (in-person or
telephone), and clinician profession were used to identify
comparable activities. Including all fixed and indirect costs,
in-person consultations with the team care manager, internist,
and physical therapist were assigned hourly costs of $271.30,
$313.60, and $145.78, respectively. DSS costs for telephone
consultations unrelated to the APT intervention by the team
internist were, on average, 90% of the costs of in-person
encounters of similar duration. Based on this observation,
team internist and care manager telephone encounters with
intervention group patients were assigned 90% of the costs of
in-person encounters of similar duration. Additional patient
care-related activities (eg, weekly case conferences and group
educational meetings) by the team care manager and internist
that exceeded the indirect care-related work associated with
normal clinical practice were assigned costs based on in-
person patient encounter rates. For intervention team, patient
care activities that could not be ascribed to individual pa-
tients, costs were assigned to patients in proportion to the
amount of time that the intervention team spent on care
directly attributable to those patients.
Costs of training time for the team care manager,
internist, and physical therapist were calculated using their
hourly salary plus benefits rates. Primary care clinicians’
training time costs were calculated using the hourly salary
plus benefits rate of the team internist for all physicians and
the main VAMC site’s average nurse practitioner hourly
salary plus benefits rate was used for all nurse practitioners.
Other costs, divided equally among intervention group pa-
tients, included a video/DVD provided to intervention group
patients ($327.50) and travel expenses related to APT team
training ($2,321.84).
A regression model of the natural logarithm of total VA
costs was used to analyze adjusted differences in costs be-
tween TAU and intervention group patients; such semi-log
models are commonly used for skewed cost data.41 We also
compute the incremental effect of the intervention and other
key predictors of costs in this nonlinear regression, for se-
lected patient profiles.42
RESULTS
Unadjusted Patient Characteristics, Outcomes,
and Costs
Table 1 summarizes baseline characteristics, quality of
life, and pain outcomes, PDFDs, as well as VA treatment
costs for intervention and TAU group patients. There were no
statistically significant differences between the 2 groups on
baseline health and demographic characteristics. Mean VA
treatment costs in the 12 months prior to study enrollment
were $6079 and $7445 for intervention and TAU patients,
respectively. Based on RMDQ scores at 3, 6, and 12 month
intervals, intervention and TAU group patients were com-
puted to have been pain disability free on average for 142 and
124 days, respectively, during the 12-month study period.
APT team activities added $1192 in costs for intervention
patients so that total VA costs were $11,263 for intervention
group patients and $8920 for TAU group patients. Figure 1
shows the distribution of log total costs for TAU and inter-
vention group patients.
Adjusted PDFDs
Table 2 shows regression models for PDFDs that pa-
tients experienced during the study period as well as for the
TABLE 1. Patient Characteristics, Outcomes, and Costs*
Variable
Intervention
Group
(n  187) Mean
(SD) or %
Treatment as
Usual Group
(n  214) Mean
(SD) or %
Demographics
Age 62.1 (11.3) 61.3 (12.3)
Sex, male 92 92
Baseline health
PHQ-9 score† 8.1 (5.7) 8.4 (6.0)
Opioid prescription 6 mo
prior to enrollment
44 42
Chronic disease score‡ 5.0 (3.1) 4.9 (3.0)
EQ-5D score§ 0.6 (0.2) 0.6 (0.2)
Roland-Morris score¶ 14.9 (4.4) 14.5 (4.4)
Outcomes
12-mo EQ-5D score 0.6 (0.2) 0.6 (0.2)
12-mo Roland-Morris score 13.3 (5.7) 14.2 (5.6)
Pain disability-free days
0–3 mo
31.3 (25.3) 30.0 (26.6)
Pain disability-free days
3–6 mo
34.4 (28.5) 30.2 (28.3)
Pain disability-free days
6–12 mo
74.1 (59.1) 63.0 (57.7)
Pain disability-free days
0–12 mo
141.8 (108.3) 124.1 (107.5)
Costs
VA treatment costs in year
prior to enrollment, $
6079 (7068) 7445 (10,899)
VA treatment costs while
enrolled in study excluding
intervention team activities, $
10,071 (14,504) 8920 (13,131)
Costs of intervention team
activities, $
1192 (405) —
Total VA costs, $ 11,263 (14,566) 8920 (13,131)
*None of the univariate differences between the intervention and treatment as usual
groups were statistically significant at the P  0.05 level.
†Patient Health Questionnaire-9 score, range 0 to 27.
‡Chronic disease score is the RxRisk-V score which uses prescription data to
determine medical comorbidities, range 0 to 45.
§EQ-5D score, range 0.109 to 1.
¶Roland-Morris Disability Questionnaire score, range 0 to 24.
Computed from Roland-Morris Disability Questionnaire scores.
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natural logarithm of total VA costs. Independent variables
included in both regression models were intervention status,
sex, age, depression severity, opioid prescription in the 6
months prior to enrollment, and baseline chronic disease
burden (RxRisk-V score44). In addition, baseline RMDQ
score was included in the PDFDs model, while VA treatment
costs in the year prior to enrollment were included in the costs
model. An alternative analysis that included baseline RMDQ
and prior-year VA treatment costs in both models yielded
results very similar to those presented below.
Baseline pain disability accounted for most of the explan-
atory power of the pain disability model (R2  0.38)—each
unit increase in pain as measured by the baseline RMDQ score
predicted 18.7 fewer PDFDs (P  0.001). A unit increase in
disease burden as measured by the chronic disease score
(RxRisk-V score) predicted 3.2 fewer PDFDs (P  0.016).
Patients in the intervention group experienced an average of
16.6 more PDFDs than those in the TAU group over the study
year (P  0.016).
Adjusted Costs
Patients in the APT intervention group incurred 71.5%
higher adjusted costs than those in the TAU group (P 
0.001). Among SEACAP patients, each one-year increase in
age was associated with a 0.9% increase in costs (P  0.03).
A one-unit increase in severity of depression measured by the
Patient Health Questionnaire-9 score (PHQ-9) was associated
with a 2.1% increase (P  0.012), while a one-unit increase
in the baseline chronic disease burden (RxRisk-V score)
resulted in a 7.9% increase (P  0.001) in costs. A 1%
increase in VA treatment costs in the year prior to study
enrollment was associated with a 0.45% increase (P 0.001)
in costs incurred during the study period.
Adjusted Incremental Effects of the Intervention
and Patient Characteristics on Costs
Table 3 presents the predicted 12-month mean TAU
and intervention group VA costs for patients with 3 different
profiles. To further illustrate the variation in these costs,
Table 3 provides estimates of the incremental dollar effects of
selected changes in patient baseline characteristics, and
shows how changes in patient attributes can alter the cost of
a PDFD produced by the intervention. The sizes of changes in
baseline continuous variables were chosen to approximate 1
standard deviation. A smearing estimator was used in all
retransformations45; an analysis of error terms from the cost
regression found no evidence of heteroscedasticity.
TABLE 2. Regression Models for Pain Disability-Free Days and Total Costs
Variable
Pain Disability-Free Days
(n  346; R2  0.66)
Log Total Costs*
(n  398; R2  0.46)
Regression Coefficient
(95% CI) P
Regression Coefficient
(95% CI) P
Intercept 409.9 (364.5, 455.4) 0.001 3.4 (2.6, 4.3) 0.001
Intervention (reference category-
treatment as usual group)
16.6 (3.1, 30.1) 0.016 0.5 (0.4, 0.7) 0.001
Demographics
Female 12.3 (38.5, 13.8) 0.355 0.2 (0.1, 0.6) 0.147
Age 0.2 (0.4, 0.8) 0.558 0.0 (0.0, 0.0) 0.03
Baseline health
PHQ-9 score† 0.5 (1.9, 0.9) 0.468 0.0 (0.0, 0.0) 0.012
Opioid prescribed 6 mo prior
to enrollment
7.7 (23.4, 8.0) 0.337 0.0 (0.2, 0.3) 0.662
Chronic disease score‡ 3.2 (5.8, 0.6) 0.016 0.1 (0.0, 0.1) 0.001
RMDQ score§ 18.7 (20.6, 16.9) 0.001 — —
Costs
VA treatment costs in year
prior to enrollment
— — 0.4 (0.4, 0.5) 0.001
*The estimate of the percentage impact of an independent variable on costs is related to the variable’s regression coefficient (B)
as follows: 100  B for a unit change in a continuous predictor, and 100  (exp(B)  1) for a dichotomous predictor (43). When
the predictor variable is also expressed as a natural logarithm (costs in 12 months preceding study enrollment in the model in Table
2), then the variable’s regression coefficient is interpreted as the predicted percentage change for a 1% change in the value of the
predictor.
†Patient Health Questionnaire-9 score, range 0 to 27.
‡Chronic disease score is the RxRisk-V score which uses prescription data to determine medical comorbidities, range 0 to 45.
§Roland-Morris Disability Questionnaire score, range 0 to 24.
FIGURE 1. Distribution of costs for TAU and intervention
group patients.
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Profile 1 depicts a patient with baseline characteristics
close to the mean for those enrolled in SEACAP. Profiles 2
and 3 depict patients with characteristics typically associated
with lower and higher costs, respectively. For the patient in
Profile 1, the APT intervention predicts a $6035 increase in
costs; the cost per PDFD produced by the APT intervention
is $364. Profile 2 reflects a younger, female veteran with a
relatively low burden of chronic disease and depression, and
relatively low costs in the year preceding enrollment in
SEACAP. For such a patient, the predicted increase in costs
due to the APT intervention is $2701, and $162 is the
predicted cost of a PDFD produced by the intervention.
Profile 3 represents an older male veteran with high burdens
of chronic disease and depression, as well as high costs in the
year prior to enrollment. The predicted increase in costs due
to APT is $18,554 for such a patient, and the predicted cost
per PDFD produced is $1117.
DISCUSSION
We previously found that a collaborative approach to
treating chronic pain in a primary care setting was moderately
effective in decreasing pain-related disability, pain interfer-
ence, pain intensity, and depression severity scores compared
with usual care over a 12-month period. We report here that
the intervention resulted in more PDFDs compared with usual
care. The intervention group had significantly higher costs
than the usual care group, likely attributable to the cost of the
intervention as well as changes in treatment as a result of the
intervention.
With an increased average cost of about $2300 per
patient for the intervention over TAU during the study year,
our findings fall on the low end of costs for commonly-used
chronic pain interventions. The average number of direct
patient contacts (in-person or telephone) with the APT inter-
vention team was approximately 11, which corresponds to
$209 per contact. In comparison, the costs of visits to phys-
ical therapists and chiropractors were $221 and $185 in 1995
dollars, respectively, per month in a randomized back pain
study,46 which translates to about $2600 and $2200 per year.
Management of pain with medication often exceeds $4000
per year while the minimum cost of lumbar surgery is
estimated at $15,000.3
Previous studies of other collaborative care interven-
tions, in particular for depression and panic disorder, have
shown much lower intervention costs than we found.47–49
APT participants experienced an average of 16 more PDFDs
over 12 months than those in usual care, resulting in a cost of
$364 per PDFD for a typical participant. Yet, in a collabo-
rative care intervention aimed at reducing depression among
older adults, intervention patients had 107 more depression-
free days over 24 months than usual care patients, corre-
sponding to an incremental outpatient cost per depression-
free day of $2.76.47 In another study aimed at increasing
anxiety-free days among people with panic disorder, a col-
laborative approach helped people in the intervention group
have about 75 more anxiety-free days over 12 months at a
cost savings of $4 per anxiety-free day.48 Our use of micro
cost data to identify comparable activities for patient care-
related work by the intervention team contributed to our high
estimates of intervention costs. Prior studies have used pro-
vider salary and benefits plus a markup (typically 30%) for
overhead (eg, Katon et al47), which would produce lower cost
estimates. While salary, benefits, and overhead may provide
an accurate measure of incremental costs in clinical trial
settings, using microcosts for comparable activities provides
a better estimate of costs if interventions were incorporated
into standard care.
In addition, while our primary outcome measure of
PDFDs was modeled on Lave et al’s32 method of calculating
depression-free days, psychometric differences in the mea-
sures used for depression (Hamilton Depression Rating
Scale) and pain (RMDQ), as well as differences in the
TABLE 3. Predicted Mean Costs and Incremental Effects of Predictors
Patient
Type Group
12-mo
Predicted
Mean
Costs ($)
Cost of a Pain
Disability-Free
Day
Incremental Effects on 12 mo Costs ($) (Factors)
Intervention Female
10-yr
Increase
in Age
6-Point
Increase in
Severity of
Depression
Opioid
Prescription
6 mo Prior
to
Enrollment
3-Point
Increase in
Chronic
Disease
Score
$10,000 Increase
in Treatment
Costs in yr
Prior to
Enrollment
Profile 1* TAU 8447 364 6035 2332 817 1146 398 2252 5183
Profile 1* INT 14,482 — 3998 1400 1963 684 3860 5765
Profile 2† TAU 3780 162 2701 — 366 512 178 1008 4179
Profile 2† INT 6479 — — 626 878 307 1727 4863
Profile 3‡ TAU 25,967 1117 18,554 7168 2510 3521 1226 6922 6268
Profile 3‡ INT 44,521 — 12,291 4305 6036 2103 11,867 6605
*Profile 1: 62-yr-old male veteran with depression severity of 8 on PHQ-9 scale, no opioid prescription in the 6 mo prior to enrollment, with a chronic disease score of 5 and
treatment costs of $7444 in the year preceding enrollment in the study.
†Profile 2: 35-yr-old female veteran with depression severity of 2 on PHQ-9 scale, no opioid prescription in the 6 mo prior to enrollment, chronic disease score of 2, and $2000
in treatment costs in the year prior to study enrollment.
‡Profile 3: 75-yr-old male veteran with depression severity of 16 on PHQ-9 scale, an opioid prescription in the 6 mo prior to enrollment, chronic disease score of 8, and $25,000
in treatment costs in the year prior to study enrollment.
TAU refers to treatment as usual group.
INT refers to APT intervention group.
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disorders themselves, may contribute to differences in the
numbers of disorder-free days calculated. Overall, these
methodological differences in calculation of costs and disor-
der-free days limit our ability to compare the cost-effective-
ness of APT to previous collaborative interventions.
Given the relatively high cost per PDFD, it would be
helpful to identify subgroups for which APT is more cost-
effective. For example, preliminary SEACAP analyses show
a relationship between baseline RMDQ score and likelihood
of 12 month response (defined as a 30% reduction in
RMDQ): for every unit increase in baseline RMDQ score, the
odds of response decrease by 9% (P  0.002). Additional
responder analyses are in progress. In addition, in Table 3, we
presented statistical estimates of costs for 3 types of patients,
which show that younger, female veterans with a low chronic
disease burden have predicted costs of $162 per PDFD.
Taken together, these findings suggest that APT may be more
cost effective for younger and overall healthier veterans who
have lower baseline pain-related disability. For veterans with
greater baseline pain-related disability or more chronic con-
ditions, other types of pain care (eg, referral based ap-
proaches) might be more cost effective.
Another potential approach to improving the cost-ef-
fectiveness of APT would be through economies of scale, by
treating more patients using the same resources. However,
because much of the intervention focused on individualized
care (goal-setting, treatment regimen review), we would not
expect to see much economy of scale if implemented in a
larger population. Furthermore, one-time costs such as clini-
cian and intervention team training were small contributors to
the overall cost of the intervention. In an analysis taking out
all intervention team costs, intervention group patients con-
tinued to have 26% higher adjusted costs than the TAU
group. We are currently conducting a 30-month assessment to
see if intervention treatment effects persist. If so, the inter-
vention may become cost-effective over time.
This study has several limitations. The treatment setting
of the VA system differs in many respects, including patient
demographics, from other US healthcare systems. Our study
sample was comprised largely of older white men and results
may not generalize to other populations. We had to estimate
the costs of the intervention, which were not captured in the
VA costing system; our use of costs of comparable services
may have led to overestimates relative to many other studies
that have relied on provider salary and benefits information.
For example, we assigned costs to most intervention team
activities at the same rates used for direct patient encounters.
Finally, our study looked at incremental costs from a VA
health system perspective, which does not take into account
effects of the intervention on healthcare received elsewhere.
We do note that intervention and TAU patients reported
similar numbers of contacts with outside providers.
The APT collaborative care intervention of the
SEACAP study resulted in more PDFDs and higher costs
than usual care over the 12-month follow-up period. The
wide range in cost to obtain an additional PDFD suggests that
the intervention may be quite costly for older people with
many comorbidities and long-standing pain, perhaps suggest-
ing that the intervention in its current form be targeted to
certain groups of patients. We are currently conducting a
30-month follow-up to ascertain whether the benefits experi-
enced by the intervention group are maintaining or changing
over time, which may affect the cost-benefit ratio.
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